AbbVie - 11 Year Stock Price History | ABBV

Historical daily share price chart and data for AbbVie since 2013 adjusted for splits and dividends. The latest closing stock price for AbbVie as of February 29, 2024 is 176.05.
  • The all-time high AbbVie stock closing price was 178.99 on February 27, 2024.
  • The AbbVie 52-week high stock price is 179.89, which is 2.2% above the current share price.
  • The AbbVie 52-week low stock price is 130.96, which is 25.6% below the current share price.
  • The average AbbVie stock price for the last 52 weeks is 150.79.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AbbVie Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 168.6591 158.3090 178.9900 158.3090 176.0500 14.69%
2023 144.2288 154.5875 159.9549 128.5363 153.5049 -0.23%
2022 139.4307 124.0543 161.9683 122.1798 153.8545 24.04%
2021 101.7125 92.1608 124.5215 90.4833 124.0360 32.40%
2020 77.8707 74.2500 95.0110 54.1954 93.6821 27.61%
2019 63.1487 70.0085 74.8304 51.4716 73.4126 1.50%
2018 75.1574 74.3310 93.7285 61.0800 72.3309 -0.98%
2017 56.1253 45.4646 74.1799 44.1665 73.0469 60.13%
2016 43.5678 40.3743 48.6395 36.2675 45.6176 9.88%
2015 42.9318 44.6898 49.4507 33.8286 41.5166 -6.46%
2014 37.1768 34.1376 47.2807 31.0022 44.3846 27.97%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $314.432B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $719.883B 119.88
Novo Nordisk (NVO) Denmark $545.415B 44.93
Johnson & Johnson (JNJ) United States $389.136B 15.49
Merck (MRK) United States $324.660B 85.46
Novartis AG (NVS) Switzerland $216.666B 15.01
AstraZeneca (AZN) United Kingdom $202.610B 17.95
Pfizer (PFE) United States $152.689B 14.78
Sanofi (SNY) $121.420B 10.93
Innoviva (INVA) United States $0.984B 8.87